However, the report did not say how many positions will be eliminated.

Earlier in November, Botox maker Allergan Inc accepted a $66 billion takeover bid from Actavis, ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc.

Brent Saunders had said in the interview that there are overlaps in corporate functions, including human relations and finance, the report noted. (http://bloom.bg/11QY3dX).

Actavis was not immediately available for a comment.

(Reporting By Krishna Chaithanya)

Stocks treated in this article : Allergan, Inc., Valeant Pharmaceuticals Intl Inc, Actavis PLC